title: Optic gliomas: a retrospective analysis of 50 cases.
abstract: OBJECTIVE
  Gliomas of the optic pathways are rare childhood central nervous system tumors. The treatment approach is controversial because of its rarity and the slow and unpredictable growth rates of these lesions.
  
  
  METHODS
  We reviewed 50 patients with the diagnosis of optic pathway low-grade gliomas treated between January 1980 and December 1995 at King Faisal Specialist Hospital and Research Center, Saudi Arabia. Thirty-five patients presented with chiasmatic/hypothalamic (posterior tumors), and 15 with optic nerve gliomas with or without chiasmal involvement (anterior tumors). Evidence of neurofibromatosis was present in 18 patients. Twenty-nine patients underwent surgery (total or partial resection), and 12 of these received postoperative radiotherapy (RT). Sixteen patients were treated with primary RT. The radiation dose varied between 42 and 54 Gy (median dose 50).
  
  
  RESULTS
  The overall actuarial survival rate was 87.5% at 5 years and 75% at 10 years, and the corresponding progression-free survival (PFS) rates were 69% and 62%. Patients with anterior tumors fared better than those with posterior tumors, with a 10-year PFS rate of 72% and 58%, respectively; the difference, however, was not statistically significant (p = 0.58). A PFS advantage was found in favor of patients with posterior tumors treated with RT (primary or postoperative) compared with no RT, with 5-year PFS rates of 68% vs. 42% (p = 0.03). This, however, did not translate into a survival advantage because of the success of salvage treatment.
  
  
  CONCLUSIONS
  In multivariate analysis, age (<3 vs. >3 years) emerged as the only significant determinant for PFS with patients <3 years old faring worse (p = 0.03). Neurologic and endocrine dysfunction are significant problems that need to be addressed.
authors.affiliation: Department of Oncology, Section of Radiation Oncology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia. Ykhafaga@kfshrc.edu.sa
authors.forename: Yasser
authors.initials: Y
authors.lastname: Khafaga
authors.forename: Maher
authors.initials: M
authors.lastname: Hassounah
authors.forename: Alaa
authors.initials: A
authors.lastname: Kandil
authors.forename: Imaduddin
authors.initials: I
authors.lastname: Kanaan
authors.forename: Ayman
authors.initials: A
authors.lastname: Allam
authors.forename: Gamal
authors.initials: G
authors.lastname: El Husseiny
authors.forename: Amani
authors.initials: A
authors.lastname: Kofide
authors.forename: Abdulaziz
authors.initials: A
authors.lastname: Belal
authors.forename: Mohammed
authors.initials: M
authors.lastname: Al Shabanah
authors.forename: Henrik
authors.initials: H
authors.lastname: Schultz
authors.forename: Derek
authors.initials: D
authors.lastname: Jenkin
mesh_terms: D000293:Adolescent; D000328:Adult; D000704:Analysis of Variance; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D018450:Disease Progression; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008297:Male; D020339:Optic Nerve Glioma / Q000401:mortality* / Q000628:therapy*; D012189:Retrospective Studies; D015996:Survival Rate; D013997:Time Factors; D014785:Vision, Ocular